Arbutus Biopharma Corp (ABUS)

May 01, 2026

Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey

May 01, 2026

Apr 30, 2026

5 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey

Apr 30, 2026

Apr 28, 2026

Whitefort lifts Arbutus (ABUS) economic stake to 9.8% - Stock Titan

Apr 28, 2026

Apr 24, 2026

Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat

Apr 24, 2026

Apr 23, 2026

Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran - Insider Monkey

Apr 23, 2026

Apr 22, 2026

Arbutus Drug Candidate Receives FDA Fast Track Designation - MyChesCo

Apr 22, 2026

Apr 21, 2026

ABUS (Arbutus Biopharma) Other Liabilities for Banks - GuruFocus

Apr 21, 2026

Apr 21, 2026

FDA grants Arbutus Biopharma drug fast track designation - Pennsylvania Business Report -

Apr 21, 2026

Apr 18, 2026

Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN

Apr 18, 2026

Apr 17, 2026

Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability - Insider Monkey

Apr 17, 2026

Apr 17, 2026

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm

Apr 17, 2026

Apr 16, 2026

Whitefort Capital Management, LP Increases Stake in Arbutus Biop - GuruFocus

Apr 16, 2026

Apr 15, 2026

Arbutus Biopharma (ABUS) Receives FDA Fast Track Designation for Imdusiran - GuruFocus

Apr 15, 2026

Apr 15, 2026

Arbutus Biopharma Corp ($ABUS) Former Interim President and CEO 2025 Pay Revealed - Quiver Quantitative

Apr 15, 2026

Apr 15, 2026

Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseHere's Why - MarketBeat

Apr 15, 2026

Apr 15, 2026

Arbutus Biopharma Corporation Files Form 8-K with SEC – Company Details, Address, and NASDAQ Listing Information 24252675 - Minichart

Apr 15, 2026

Apr 15, 2026

ABUS Receives Fast Track Designation from FDA for Imdusiran - GuruFocus

Apr 15, 2026

Apr 15, 2026

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - The Manila Times

Apr 15, 2026

Apr 15, 2026

[8-K] Arbutus Biopharma Corp Reports Material Event - Stock Titan

Apr 15, 2026

Apr 14, 2026

Arbutus Biopharma (ABUS) 2026 proxy adds 16.3M-share incentive plan vote - Stock Titan

Apr 14, 2026

Apr 13, 2026

Whitefort outlines 8.1% Arbutus Biopharma (ABUS) stake in amended 13D - Stock Titan

Apr 13, 2026

Apr 10, 2026

ABUS Technical Analysis | Trend, Signals & Chart Patterns | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill

Apr 10, 2026

Apr 09, 2026

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat

Apr 09, 2026

Apr 08, 2026

Arbutus reports results, announces $2.25B Moderna settlement - MSN

Apr 08, 2026

Apr 07, 2026

ABUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 07, 2026

Apr 05, 2026

Arbutus Biopharma Hits Day Low of $4.21 Amid Price Pressure - Markets Mojo

Apr 05, 2026

Apr 05, 2026

Arbutus Reports Results, Announces $2.25B Moderna Settlement - MyChesCo

Apr 05, 2026

Apr 03, 2026

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com

Apr 03, 2026

Apr 02, 2026

ABUS Stock Price, Quote & Chart | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill

Apr 02, 2026

Mar 31, 2026

ABUS Should I Buy - Intellectia AI

Mar 31, 2026

Mar 29, 2026

ABUS PE Ratio & Valuation, Is ABUS Overvalued - Intellectia AI

Mar 29, 2026

Mar 25, 2026

Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2026

Mar 24, 2026

Arbutus: Q4 Earnings Snapshot - theheraldreview.com

Mar 24, 2026

Mar 24, 2026

Arbutus Biopharma Corporation (ABUS) Form 8-K Filing Details, Key Financials, and Company Information - Minichart

Mar 24, 2026

Mar 23, 2026

Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives - simplywall.st

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma 2025 Financials: Reduced Annual Loss, Revenue GrowthNews and Statistics - IndexBox

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma earnings missed by $0.14, revenue topped estimates - investing.com

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma 2025 Annual Report: Clinical Pipeline, Patent Litigation, and Strategic Outlook - Minichart

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma Corp expected to post a loss of 4 cents a shareEarnings Preview - TradingView

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma (ABUS) Misses EPS Estimates but Exceeds Revenue Expectations - GuruFocus

Mar 23, 2026

Mar 23, 2026

Arbutus: Fourth Quarter Financial Results Overview - Bitget

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results - MarketBeat

Mar 23, 2026

Mar 23, 2026

Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement - Stock Titan

Mar 23, 2026

Mar 23, 2026

Moderna settlement reshapes Arbutus Biopharma (ABUS) with $950M payout - Stock Titan

Mar 23, 2026

Mar 23, 2026

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 23, 2026

Mar 22, 2026

Market Moves: Is Arbutus Biopharma Corporation attractive at current valuation2026 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn

Mar 22, 2026